...
首页> 外文期刊>The New England journal of medicine >Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery.
【24h】

Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery.

机译:球囊血管成形术与镍钛合金支架在股浅动脉中的植入。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Because stent implantation for disease of the superficial femoral artery has been associated with high rates of late clinical failure, percutaneous transluminal angioplasty is preferred for endovascular treatment, and stenting is recommended only in the event of suboptimal technical results. We evaluated whether primary implantation of a self-expanding nitinol (nickel-titanium) stent yielded anatomical and clinical benefits superior to those afforded by percutaneous transluminal angioplasty with optional secondary stenting. METHODS: We randomly assigned 104 patients who had severe claudication or chronic limb ischemia due to stenosis or occlusion of the superficial femoral artery to undergo primary stent implantation (51 patients) or angioplasty (53 patients). Restenosis and clinical outcomes were assessed at 6 and 12 months. RESULTS: The mean (+/-SD) length of the treated segment was 132+/-71 mm in the stent group and 127+/-55 mm in the angioplasty group. Secondary stenting was performed in 17 of 53 patients (32 percent) in the angioplasty group, in most cases because of a suboptimal result after angioplasty. At 6 months, the rate of restenosis on angiography was 24 percent in the stent group and 43 percent in the angioplasty group (P=0.05); at 12 months the rates on duplex ultrasonography were 37 percent and 63 percent, respectively (P=0.01). Patients in the stent group were able to walk significantly farther on a treadmill at 6 and 12 months than those in the angioplasty group. CONCLUSIONS: In the intermediate term, treatment of superficial-femoral-artery disease by primary implantation of a self-expanding nitinol stent yielded results that were superior to those with the currently recommended approach of balloon angioplasty with optional secondary stenting. (ClinicalTrials.gov number, NCT00281060.).
机译:背景:由于用于股浅动脉疾病的支架植入术与晚期临床失败率高相关,因此,经皮腔内血管成形术是血管内治疗的首选方法,仅在技术结果欠佳时才建议采用支架术。我们评估了自膨式镍钛诺(镍钛合金)支架的一次植入是否比通过可选的二次支架经皮腔内血管成形术所产生的解剖和临床优势更好。方法:我们随机分配了104例因狭窄或股浅动脉闭塞而导致严重c行或慢性肢体缺血的患者,进行了第一支架植入术(51例)或血管成形术(53例)。在6个月和12个月时评估再狭窄和临床结果。结果:在支架组中,治疗段的平均(+/- SD)长度为132 +/- 71 mm,在血管成形术组中为127 +/- 55 mm。血管成形术组中53例患者中的17例(占32%)进行了二次支架置入术,在大多数情况下,由于血管成形术后结果欠佳。 6个月时,支架组血管造影的再狭窄率为24%,血管成形术组为43%(P = 0.05);在12个月时,双工超声检查的发生率分别为37%和63%(P = 0.01)。与血管成形术组相比,支架组的患者在6和12个月的跑步机上能够走得更远。结论:在中期,通过自植入镍钛诺支架的初次植入治疗股浅动脉疾病产生的结果优于目前推荐的球囊血管成形术和可选的二次支架治疗。 (ClinicalTrials.gov编号,NCT00281060。)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号